KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Interest & Investment Income (2019 - 2025)

Historic Interest & Investment Income for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $7.1 million.

  • Royalty Pharma's Interest & Investment Income fell 2175.5% to $7.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $33.6 million, marking a year-over-year decrease of 2904.76%. This contributed to the annual value of $33.6 million for FY2025, which is 2904.76% down from last year.
  • As of Q4 2025, Royalty Pharma's Interest & Investment Income stood at $7.1 million, which was down 2175.5% from $6.9 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Interest & Investment Income ranged from a high of $43.9 million in Q4 2022 and a low of $6.5 million during Q4 2023
  • Its 5-year average for Interest & Investment Income is $14.3 million, with a median of $11.8 million in 2021.
  • Per our database at Business Quant, Royalty Pharma's Interest & Investment Income soared by 67258.98% in 2021 and then plummeted by 8517.78% in 2023.
  • Quarter analysis of 5 years shows Royalty Pharma's Interest & Investment Income stood at $10.6 million in 2021, then skyrocketed by 312.19% to $43.9 million in 2022, then tumbled by 85.18% to $6.5 million in 2023, then soared by 39.03% to $9.0 million in 2024, then fell by 21.76% to $7.1 million in 2025.
  • Its Interest & Investment Income was $7.1 million in Q4 2025, compared to $6.9 million in Q3 2025 and $8.3 million in Q2 2025.